Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

2- In the Registration Statement, NRx accuses Relief of misleading them and Relief's public shareholders about the stability of the formulation of aviptadil that Relief brought to the parties' collaboration. Relief reiterates, once again, that in its opinion, there is no truth to these allegations, and that NeuroRx was expressly tasked with developing a stable formulation of aviptadil under the Collaboration Agreement. Further, Relief reiterates, once again, that it never guaranteed that it already had an 18-month shelf stable product, and no such statements are made in the Collaboration Agreement, which contains the entire agreement between the parties. Finally, Relief once again reiterates its belief that the version of aviptadil that was and is being used by NeuroRx in its clinical trials is the drug version covered by the Collaboration Agreement.

https://relieftherapeutics.com/newsblog/relief-therapeutics-comments-on-certain-statements-made-by-nrx-pharmaceuticals-in-its-registration-statement-on-form-s-1-filed-on-september-3-2021